
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$848.85M
Market Cap
-
P/E Ratio
-1.4
EPS
$31.04
52 Week High
$14.57
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $107M |
| Total Revenue | $283M |
| Cost Of Revenue | $176M |
| Costof Goods And Services Sold | $176M |
| Operating Income | -$74M |
| Selling General And Administrative | $88M |
| Research And Development | $49M |
| Operating Expenses | $181M |
| Investment Income Net | - |
| Net Interest Income | $31M |
| Interest Income | $31M |
| Interest Expense | $170K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $25M |
| Income Before Tax | -$52M |
| Income Tax Expense | -$8.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$44M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$74M |
| Ebitda | -$49M |
| Net Income | -$43M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $107M |
| Total Revenue | $283M |
| Cost Of Revenue | $176M |
| Costof Goods And Services Sold | $176M |
| Operating Income | -$74M |
| Selling General And Administrative | $88M |
| Research And Development | $49M |
| Operating Expenses | $181M |
| Investment Income Net | - |
| Net Interest Income | $31M |
| Interest Income | $31M |
| Interest Expense | $170K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $25M |
| Income Before Tax | -$52M |
| Income Tax Expense | -$8.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$44M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$74M |
| Ebitda | -$49M |
| Net Income | -$43M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Fulgent Genetics, Inc. is a leading provider of advanced genetic testing and diagnostic solutions, headquartered in Temple City, California. The company specializes in a wide range of services, from comprehensive genomic analyses to COVID-19 diagnostics, all designed to provide actionable insights that enhance patient care. Fulgent's commitment to precision medicine and innovation not only reinforces its leadership in the genetic testing arena but also positions it favorably for continued growth and strategic expansion in the dynamic healthcare market. With a robust technological foundation and a focus on addressing evolving public health needs, Fulgent is poised to capitalize on future opportunities.